Overview

Accel Research Sites Network was acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to expand its clinical trial site network and clinical trial execution capabilities

Significance

Specialized research sites with multi-therapeutic expertise play a crucial role in successfully bringing new drugs and treatments to market. They offer end-to-end support services handling patient recruitment, regulatory compliance, and data collection within compressed timelines. These sites ensure efficient trial execution and their expertise is valuable for sponsors navigating the complexities of the clinical development process. Clinical research sites’ contributions are instrumental in advancing public health on a global scale.

Accel Research Sites Network (“Accel”) is a highly regarded research site network dedicated to advancing clinical research and helping novel medicines reach the patients who need them for nearly 25 years. With a highly attractive portfolio of research sites, they specialize in streamlining the clinical trial process, expediting the development of life-saving treatments. With 2,500+ completed trials and 22 research sites in the Southeast region of the US, Accel is a leader in medical research. This market leadership position made Accel the ideal acquisition for Alcanza to expand its clinical trial site network and overall capabilities.

Crosstree’s Role

Crosstree’s expertise in both the clinical trial site and deep understanding of Accel’s unique value proposition helped the firm advise Accel in identifying Alcanza as the ideal transaction partner through:

• Evaluating a broad slate of potential financial and strategic partners
• Leveraging market expertise to identify the ideal partner to maximize synergies and optimize outcome for both parties
• Developing and articulating a strong value proposition which connected client capabilities with market trends to weave a compelling narrative for potential buyers